LakeShore Biopharma Co., Ltd (NASDAQ: LSB), a prominent biopharmaceutical company, has successfully regained compliance with Nasdaq's minimum bid price requirement after experiencing non-compliance due to a prolonged period of its share price falling below $1.00. As of October 21, 2024, the company
Artificial Intelligence (AI) has the potential to revolutionize drug discovery and development, offering numerous advantages that could transform current practices in the biopharmaceutical industry. By merging Accenture's advanced capabilities in AI scaling with the innovative ITO™ platform
In a remarkable advancement in the fight against malaria, The Medicines for Malaria Venture (MMV) and Quotient Sciences have initiated a Phase 1 clinical trial for MMV371, a long-acting injectable (LAI) malaria preventive. Conducted with healthy volunteers in Nottingham, UK, this trial represents a
Switzerland has established itself as a global leader in the biotech industry, making significant advancements in areas such as cancer treatment, immunotherapy, gene and cell therapy, and more. With a strong focus on personalized and precision medicine, the Swiss biotech sector thrives on
Clinical trials have long faced significant challenges in enrolling and retaining participants, a problem exacerbated by logistical and engagement difficulties inherent in the clinical trial process. Recent data highlights that up to one-third of trial participants drop out before the studies are
In a significant leap forward for oncology, the U.S. Food and Drug Administration (FDA) has given the green light to Astellas Pharma Inc.'s VYLOY (zolbetuximab-clzb) for treating adults with advanced, unresectable, or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or
